Robert Walczak

This inventor holds 25 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent and 16 EPO patents. Top assignee: Genfit. Active years: 2018-2026.

USPTO Granted Patents = 25 (Patent Applications = 12)

% Patents Active = 92.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 16 (Patent Applications = 24)

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 50(Granted Patents)

Company Filing History:

25 out of 72

Genfit

patents

Years Active: 2018-2026

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12678427 - Combination therapy having antioxydant properties (2026-07-14),

2. 12458612 - Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists (2025-11-04),

3. 12391712 - Phosphate derivatives of RORgamma modulators and uses thereof (2025-08-19),

4. 12208087 - Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation (2025-01-28),

5. 12053456 - Pharmaceutical compositions for combination therapy (2024-08-06),

6. 11974997 - RORgamma modulators and uses thereof (2024-05-07),

7. 11590108 - Pharmaceutical compositions for combination therapy (2023-02-28),

8. 11484517 - Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor (2022-11-01),

9. 11478440 - Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent (2022-10-25),

10. 11400078 - Methods of treatment for cholestatic and fibrotic diseases (2022-08-02),

11. 11191749 - Pharmaceutical compositions for combination therapy (2021-12-07),

12. 11160801 - RORgamma modulators and uses thereof (2021-11-02),

13. 11103484 - Methods of treatment for cholestatic and fibrotic diseases (2021-08-31),

14. 11077115 - Rorgamma modulators and uses thereof (2021-08-03),

15. 11052092 - N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases (2021-07-06),

Title: Innovations by Robert Walczak in Immune Disease Treatment

Introduction

Robert Walczak is an accomplished inventor based in Lille, France, known for his significant contributions to the field of pharmaceutical sciences. With a prolific portfolio of 22 patents, he focuses primarily on the treatment of immune diseases and inflammation. His work showcases a commitment to advancing medical therapies through innovative combination approaches.

Latest Patents

Among Robert Walczak’s latest patents is a groundbreaking combination of nitazoxanide and elafibranor designed for treating immune diseases or inflammation. This invention details a combination product that includes nitazoxanide (NTZ) or an analogue thereof, alongside a PPAR agonist, marking a significant advancement in therapeutic options for patients suffering from immune-related conditions. Additionally, he has developed pharmaceutical compositions for combination therapy, further emphasizing his dedication to enhancing treatment efficacy through innovative product formulations.

Career Highlights

Robert works at Genfit, where he leverages his expertise in pharmaceutical research to innovate and develop therapies targeting complex health issues. His efforts within the company have positioned Genfit as a key player in the pharmaceutical landscape, particularly in the realm of metabolic and liver diseases.

Collaborations

In his journey, Robert collaborates with notable professionals like Carole Belanger and Philippe Delataille. These partnerships have fostered a collaborative environment at Genfit, promoting the sharing of knowledge and innovation in therapeutic development.

Conclusion

Overall, Robert Walczak's dedication to advancing pharmaceutical science through his patents and collaborations exemplifies the spirit of innovation in healthcare. His work continues to pave the way for the development of effective treatments for immune diseases, highlighting the importance of research and collaboration in the field.